Abstract
Adecade in development, Dendreon’s prostate cancer vaccine, sipuleucelT (Provenge), has become the first therapeutic cancer vaccine to receive approval from the U.S. Food and Drug Administration. The FDA approved Provenge in April to treat metastatic castration (hormone)-resistant prostate cancer. In the phase III trial, known as IMPACT, patients taking Provenge had a 4.1-month median improvement in overall survival. Although 4 months is a modest increase, some view Provenge’s approval as a milestone for the entire class of immunotherapeutic cancer vaccines. “Provenge’s approval is a watershed,” said
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
